Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Triple-Negative Breast Carcinoma
Interventions: DRUG: Gemcitabine|DRUG: Gemcitabine Hydrochloride|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Mirvetuximab Soravtansine|OTHER: Pharmacological Study
Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)